Skip to content
Newcells Secure Investment
23rd February, 2021

Newcells Biotech secures over £5m for 3D tissue models

Newcastle-based human stem cell model specialists, Newcells Biotech, have secured a total of £5.25m worth of funding to accelerate their growth plans in the international life sciences market.The funding…

Read update
Developing a 3D in vitro proximal tubule model for chronic toxicity studies
26th January, 2021

Developing a 3D in vitro proximal tubule model for chronic toxicity studies

The kidney proximal tubule is of key interest in drug discovery. This is due to its primary role in the excretion and reabsorption of xenobiotics, such as drugs and…

Read update
Covid 19 Update Banner
13th January, 2021

Covid-19 action plan – 2021 update

In line with our previous Covid-19 Action Plan, Newcells Biotech has continued to review and invest in measures to reduce the risk to its staff and…

Read update
Newcells Biotech aProximate Model
14th December, 2020

Improved in vitro renal tubular drug transport modelling to meet regulatory & development cost challenges

The proximal tubule is key due to its role in the excretion and reabsorption of many xenobiotic compounds. Due to the high costs associated with drug discovery and the…

Read update
Drug Target Review
3rd December, 2020

Development of a physiologically relevant lung model for understanding SARS-CoV-2 infection

Covid-19 is known to infect the lungs. However, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, we…

Read update
Structure of the newcells retinal model
27th October, 2020

Diagnosing unresolved Stargardt disease using retina-specific splicing isoforms obtained from retinal organoids

At Newcells Biotech, we specialise in the large-scale production of retinal organoids for the purpose of in vitro toxicology efficacy studies and disease modelling. Our differentiation protocols generate organoids which…

Read update
Development of functioning in vitro lung assay for modelling Covid-19 infection
31st July, 2020

Development of functioning in vitro lung assay for modelling Covid-19 infection

Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform…

Read update
Newcells scales up its operations in the biosphere
26th June, 2020

Newcells scales up its operations in The Biosphere

Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory 

Read update
An image of a needle being readied to administer a vaccine
11th June, 2020

An overview of vaccine development & sub-types

Vaccination can be regarded as one of biomedicines biggest triumphs. Since Edward Jenner pioneered the smallpox vaccine in 1798, subsequent morbidity and mortality rates have 

Read update
Newcells Biotech aProximate Model
5th May, 2020

Biologics & the kidney – importance of transport & safety assessment

Biologics represent a new modality of drug molecules which is rapidly expanding in market share and in the number of biologics gaining regulatory approval each year.  Biologics are defined…

Read update
Image of the SARS-CoV-2
22nd April, 2020

The Human Cell Atlas – an aid to understanding COVID-19 & a valuable tool in the development of hiPSC models

The outbreak of the novel viral disease, COVID-19, caused by the severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has led to worldwide health and economic catastrophe.1 Almost 2 million…

Read update
An experiment being carried out
6th April, 2020

NB testing an in vitro model of the human lung epithelium for application in the fight against SARS-CoV-2

Internationally renowned company, Newcells Biotech, are using their established expertise in human induced pluripotent stem cell (hiPSC) technology to test their existing model of the human lung epithelium as…

Read update

Get our latest updates straight to your inbox